Loading stock data…
NGNE
$26.85+0.76 (+2.91%)
Market ClosedLast close May 1
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neurogene Inc. in the Healthcare sector is trading at $26.85. The stock is currently 28% below its 52-week high of $37.27, remaining 23.1% above its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why NGNE maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.85
Potential Upside
5%
Whystock Fair Value$28.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$76.43+184.7%
Range$46.00 – $180.00
Fundamentals
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$425.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.11%
Volume
Today's trading volume
130,562
Recent News
Neurogene: Q4 Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of $1.12. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share.
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene (NASDAQ:NGNE) CEO and founder Rachel McMinn outlined the company’s progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lea
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’ earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the ... Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim’s 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a “de